Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome.
Chong Hyun ShinKi-Hye KimSubbiah JeevaSang Moo KangPublished in: Cells (2021)
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) gave rise to the coronavirus disease 2019 (COVID-19) pandemic. A strong correlation has been demonstrated between worse COVID-19 outcomes, aging, and metabolic syndrome (MetS), which is primarily derived from obesity-induced systemic chronic low-grade inflammation with numerous complications, including type 2 diabetes mellitus (T2DM). The majority of COVID-19 deaths occurs in people over the age of 65. Individuals with MetS are inclined to manifest adverse disease consequences and mortality from COVID-19. In this review, we examine the prevalence and molecular mechanisms underlying enhanced risk of COVID-19 in elderly people and individuals with MetS. Subsequently, we discuss current progresses in treating COVID-19, including the development of new COVID-19 vaccines and antivirals, towards goals to elaborate prophylactic and therapeutic treatment options in this vulnerable population.
Keyphrases
- coronavirus disease
- sars cov
- respiratory syndrome coronavirus
- metabolic syndrome
- low grade
- insulin resistance
- risk factors
- high grade
- emergency department
- oxidative stress
- cardiovascular events
- adipose tissue
- cardiovascular risk factors
- endothelial cells
- coronary artery disease
- physical activity
- weight loss
- drug induced
- skeletal muscle
- stress induced
- single molecule